Construction of IL-1 signalling pathway correlation model in lung adenocarcinoma and association with immune microenvironment prognosis and immunotherapy: Multi-data validation

Front Immunol. 2023 Feb 10:14:1116789. doi: 10.3389/fimmu.2023.1116789. eCollection 2023.

Abstract

Numerous studies have confirmed the inextricable link between inflammation and malignancy, which is also involved in developing lung adenocarcinoma, where IL-1 signalling is crucial. However, the predictive role of single gene biomarkers is insufficient, and more accurate prognostic models are needed. We downloaded data related to lung adenocarcinoma patients from the GDC, GEO, TISCH2 and TCGA databases for data analysis, model construction and differential gene expression analysis. The genes of IL-1 signalling-related factors were screened from published papers for subgroup typing and predictive correlation analysis. Five prognostic genes associated with IL-1 signalling were finally identified to construct prognostic prediction models. The K-M curves indicated that the prognostic models had significant predictive efficacy. Further immune infiltration scores showed that IL-1 signalling was mainly associated with enhanced immune cells, drug sensitivity of model genes was analysed using the GDSC database, and correlation of critical memories with cell subpopulation components was observed using single-cell analysis. In conclusion, we propose a predictive model based on IL-1 signalling-related factors, a non-invasive predictive approach for genomic characterisation, in predicting patients' survival outcomes. The therapeutic response has shown satisfactory and effective performance. More interdisciplinary areas combining medicine and electronics will be explored in the future.

Keywords: immune checkpoint; immunotherapy; lung adenocarcinoma; single cell; tumour microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma of Lung* / therapy
  • Humans
  • Immunotherapy
  • Interleukin-1 / genetics
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / therapy
  • Prognosis
  • Tumor Microenvironment / genetics

Substances

  • Interleukin-1

Grants and funding

This work was supported by the Ningbo Clinical Research Centre for Thoracic and Breast Tumours (2021L002). The Ningbo 2025 Major Science and Technology Innovation Project (2019B10039), the Ningbo Natural Science Foundation (2022J256), and the Ningbo Leading Medical and Health Sciences Project (2022-F02).